Drug Approval | January 26, 2024
Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg
Gabapentin is indicated for the management of Postherpetic Neuraligia
Gabapentin is indicated for the management of Postherpetic Neuraligia
The registered capital of the newly founded company is € 50 million
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
An accomplished R&D leader and champion of the application of AI to drug discovery
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Subscribe To Our Newsletter & Stay Updated
